A publicly traded Danish medical marijuana operator Abdomen ache and a German pharmaceutical firm targeted on hashish ADREXpharma are prepared to supply a brand new and modern medical hashish oil for German sufferers.
The businesses have obtained approval to promote new medical marijuana oil in Germany, with the primary gross sales anticipated within the fourth quarter of 2024.
“Our Astrum 10-10 oil was first accepted on the market in Australia and now we’re including Germany because the second market,” CEO of Stenocare, Thomas Skovlund Schnegelsberg stated “In our opinion, the brand new Astrum product is really revolutionary for the whole medical hashish trade and for German sufferers. In brief, our new oil know-how solves key challenges within the medical hashish trade : 1) doubles the absorption of cannabinoids, 2) gives a uniform absorption within the blood by way of people, 3) the utmost focus of the drug is reached in half the time, and, lastly, 4 ) could be supplied within the physique with larger uniformity, no matter meals consumption.
The brand new product is a THC-CBD 10-10 oil in a 30 ml bottle, marked “Astrum”, and the corporate has the exclusivity on this planet for this patented oil know-how.
Stenocare Astrum oil is predicated on modern know-how, which has the potential to extend the bioavailability of cannabinoids within the blood of sufferers. In line with the corporate, the oil faces a well known problem with the dose of medication and making certain the constant consumption of the lively elements within the blood. With the Astrum product, Stenocare accomplished a pharmacokinetic (PK) examine in canines that documented two necessary parameters within the lymphatic system that may enhance bioavailability:
- Parameter 1 – uptake within the blood: In line with the PK examine, Astrum improves absorption within the blood by an element of two.6 in comparison with a reference MCT-oil product in the marketplace. The low and inconsistent uptake of the drug within the blood between sufferers is a well known problem within the pharmaceutical trade, which applies to most medicine.
- Parameter2 –timetomaximpact: In line with the PK examine, the product Stenocare Astrum reduces the time from the dose to the utmost impact from 2-4 hours to only one hour.
“Though bioavailability has been a key problem for a very long time within the medical hashish trade, it’s our expertise that actual knowledge from a pharmacokinetic examine relating to the problem has not been obtainable with a commercially obtainable product This places Stenocare in a really sturdy place to be the primary mover within the subsequent era of medical hashish oil merchandise, which has the potential to revolutionize the market,” added Schnegelsberg.
https://www.benzinga.com/markets/hashish/24/08/40251407/danish-cannabis-company-stenocare-to-launch-innovative-medical-marijuana-oil-in-germany
